<DOC>
	<DOCNO>NCT03071653</DOCNO>
	<brief_summary>A randomize control trial test potential safety efficacy LCSD patient heart failure due non-ischemic ischemic cardiomyopathy University Cape Town . Left Cardiac Sympathetic Denervation ( LCSD ) surgical intervention modulates autonomic innervation cardiac system . This important : ] sympathetic parasympathetic tone profound effect threshold ventricular tachyarrhythmias-the main cause sudden cardiac death population ; b ] autonomic dysfunction ( characterize imbalance sympathetic parasympathetic activation ) , play important detrimental role pathophysiology progression heart failure .</brief_summary>
	<brief_title>Left Cardiac Sympathetic Denervation Cardiomyopathy Feasibility Pilot Study</brief_title>
	<detailed_description>STUDY SUMMARY TITLE Left Cardiac Sympathetic Denervation ( LCSD ) Cardiomyopathy Study DESIGN Phase II feasibility parallel randomise control trial ( RCT ) AIMS Assess feasibility safety LCSD patient cardiomyopathy heart failure OUTCOME MEASURES Recruitment rate , retention , follow-up safety POPULATION 30 patient heart failure secondary cardiomyopathy ELIGIBILITY Adult participant ischemic non-ischemic cardiomyopathy DURATION 18 month follow METHODS : Participants randomize receive LCSD addition optimal medical therapy intervention arm ( 15 patient ) optimal medical therapy active control arm ( 15 patient ) . Participants would recruit inpatient outpatient general medical cardiology ward clinic Groote Schuur Hospital patient syndrome heart failure frequently refer subspecialty evaluation management . Eligible patient meet inclusion criterion would randomize undergo LCSD addition optimal medical therapy ( intervention arm ) receive standard optimal medical therapy ( active placebo ) . Optimal therapy patient cardiomyopathy heart failure currently consist ace-inhibitor angiotensinogen receptor blocker , beta-blocker , mineralocorticoid receptor antagonist without loop diuretic , digoxin . All patient study would receive implantable loop recorder allow accurate determination episode symptomatic asymptomatic ventricular tachyarrhythmias . In order lose clinical outcome information obtain pilot phase study , would propose assess pre-specified feasibility safety aspect study keep data efficacy outcomes blind inclusion fully power main study . The LCSD procedure The procedure involve surgical removal lower half leave stellate ganglion ( T1 ) thoracic ganglion ( T2-T4 ) , thereby remove pro-arrhythmic noradrenergic input ventricle ( 3 ) . LCSD raise ventricular fibrillation threshold without impair cardiac contractility reduce heart rate . LCSD result pre-ganglionic denervation , thus prevent re-innervation produce permanent antifibrillatory effect . This procedure perform video-assisted thoracoscopic surgery ( VATS ) usually less 45 minute conduct thoracic surgeon Groote Schuur Hospital . The lead thoracic surgeon ( J.R. ) large experience perform procedure indication hyperhidrosis 200 patient ( personal communication ) . This experienced thoracic surgeon lead team thoracic surgeon ( T.P. , L.M . ) perform procedure . Implantable loop recorder ( ILR ) insertion The implantable loop recorder small device insert end LCSD procedure thoracic surgeon enrolment optimal medical therapy arm cardiologist . This loop recorder insert sterile condition catheter laboratory operating theatre . In catheter laboratory , device insert local anaesthetic , subcutaneously leave precordium usually take less 15 minute . The implantable loop recorder well-established device quantify detect atrial ventricular tachyarrhythmias excellent safety record . The device battery life 3 year remove via small skin incision end study . Implantable loop recorder insertion carry risk know major complication . There minimal risk ( &lt; 1 % ) complication ( infection , bleed ) device implant subcutaneously . Potential complication include superficial skin infection readily respond antibiotic . Device removal easy perform seldom require . Optimal Medical Therapy All eligible patient heart failure depress leave ventricular systolic function receive guideline evidence base optimal tolerated medical therapy . The level risk associate optimal medical therapy consider low . For majority patient heart failure depress leave ventricular systolic function include : 1 . A renin angiotensin system blocker high tolerate dos ( e.g. , enalapril 10mg twice daily equivalent ) 2 . A mineralocorticoid receptor antagonist ( e.g. , Spironolactone 25-50mg daily equivalent ) 3 . A Beta-blocker ( e.g. , Carvedilol 25mg twice daily equivalent ) 4 . The use loop diuretic digitalis clinically drive use discretion attend clinician</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>At least 18 year age New York Heart Association ( NYHA ) II/III stable heart failure due ischemic nonischemic cardiomyopathy Left Ventricular Ejection Fraction &lt; =35 % base Echocardiogram , ERNA MRI perform last 12 month . For purpose study , Ischemic cardiomyopathy define Left Ventricular systolic dysfunction ( Ejection Fraction &lt; 35 % ) associate 75 % narrow least 1 3 major coronary artery , document history ST elevation myocardial infarction significant regional wall motion abnormality echocardiogram . Nonischemic cardiomyopathy define Left Ventricular systolic dysfunction &lt; 35 % absence know coronary artery disease regional wall motion abnormality echocardiography . No history prior cardiac arrest sustain ( &gt; 30 second &lt; 30 haemodynamically unstable ) ventricular tachyarrhythmia . Signed informed consent form available IsiXhosa , Afrikaans English . History prior unexplained syncope , sudden cardiac arrest ventricular arrhythmia Peripartum cardiomyopathy cardiomyopathy associate thyrotoxicosis History coronary revascularization percutaneous intervention precede 3 month Myocardial infarction precede 1 month NYHA IV enrollment Patient take antiarrhythmic drug ( include betablockers ) Pregnancy Any noncardiac condition associate high likelihood death trial major organ dysfunction malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Left Cardiac Sympathetic Denervation</keyword>
</DOC>